Saudi Arabian pharmaceutical company Jamjoom Pharma is set to establish a new drug production facility in Uzbekistan, according to a statement from the Ministry of Health. During a recent visit to Riyadh, Farhad Tashpulatov, Deputy Head of the Ministry, met with Mahmud Jamjoom, the company's head, to discuss the project.
The planned modern plant will be located in the Tashkent Pharma Park cluster and is expected to commence operations in the third quarter of 2025. The project will be financed through direct foreign investment, marking a step in enhancing Uzbekistan's pharmaceutical manufacturing capabilities.
Additionally, the discussions included the registration of 30 different drugs that Jamjoom Pharma plans to produce in Uzbekistan. Following the talks, a partnership agreement was successfully signed, solidifying the collaboration between the two parties.
The negotiations also explored the proposal from InterHealth Hospital Medical to take over the management of several medical institutions, including two branches of the Republican Scientific and Practical Center of Oncology and Medical Radiology, as well as a new multidisciplinary medical center for adults planned for Tashkent.
This development follows Jamjoom Pharma's investment agreement signed in 2022, where the company committed to investing $52mn to penetrate the Central Asian market.
Earlier, Miahona, a Saudi company, has signed a Development Agreement with Uzbekistan's Ministry of Investment, Industry, and Trade, and Uzsuvtaminot Company to enhance water and sewage treatment facilities in the Fergana Valley and Jizzakh Region.
The one-year agreement focuses on developing treatment plants under a Build-Own-Operate-Transfer (BOOT) model and providing Enhanced Operations and Maintenance (EOM) services. Miahona plans to establish four new sewage treatment plants and assess five existing operations and maintenance projects in the region.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)